WordNet

a quantitative or qualitative test of a substance (especially an ore or a drug) to determine its components; frequently used to test for the presence or concentration of infectious agents or antibodies etc.
analyze (chemical substances)
a substance that is undergoing an analysis of its components
an appraisal of the state of affairs; "they made an assay of the contents"; "a check on its dependability under stress" (同)check
a written report of the results of an analysis of the composition of some substance
hardy and sure-footed animal smaller and with longer ears than the horse
a pompous fool

PrepTutorEJDIC

(金属の品質・鉱石の金属含有量・薬品の)分析,試金 / 試金物,分析物 / …'を'試金する,分析する
ロバ / ばか者
《米俗》しり,けつ(《英俗》arse)

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/01/15 11:51:47」(JST)

wiki en

[Wiki en表示]

Schild regression analysis, named for Heinz Otto Schild, is a useful tool for studying the effects of agonists and antagonists on the cellular response caused by the receptor or on ligand-receptor binding.

Using a dose-response curve or an equivalent curve with concentration and binding %, it is possible to determine the dose ratio, this is a measure of the potency of a drug; it is obtained by dividing the increased equilibrium constant due to drug inhibition by the equilibrium constant without the drug. A Schild plot is a double logarithmic plot, typically Log(dr-1) as the ordinate and Log[B] as the abscissa. This is because a competitive drug B will have a linear plot with the $dr=1+[B]/K_{B}$ . These experiments must be carried out on a very wide range (therefore the logarithmic scale) as the mechanisms differ over a large scale, such as at high concentration of drug.

Schild regression for ligand binding

Although most experiments use cellular response as a measure of the effect, the effect is, in essence, a result of the binding kinetics; so, in order to illustrate the mechanism, ligand binding is used. A ligand A will bind to a receptor R according to an equilibrium constant :

Although the equilibrium constant is more meaningful, texts often mention its inverse, the affinity constant (K_aff = k₁/k_-1): A better binding means an increase of binding affinity.

The equation for simple ligand binding to a single homogeneous receptor is

This is the Hill-Langmuir equation, which is practically the Hill equation (biochemistry) described for the agonist binding. In chemistry, this relationship is called the Langmuir equation, which describes the adsorption of molecules onto sites of a surface (see adsorption).

[R]total is the total number of binding sites, and when the equation is plotted it is the horizontal asymptote to which the plot tends; more binding sites will be occupied as the ligand concentration increases, but there will never be 100% occupancy. The binding affinity is the concentration needed to occupy 50% of the sites; the lower this value is the easier it is for the ligand to occupy the binding site.

The binding of the ligand to the receptor at equilibrium follows the same kinetics as an enzyme at steady-state (Michaelis-Menten equation) without the conversion of the bound substrate to product.

Agonists and antagonists can have various effects on ligand binding. They can change the maximum number of binding sites, the affinity of the ligand to the receptor, both effects together or even more bizarre effects when the system being studied is more intact, such as in tissue samples. (Tissue absorption, densitization, and other non equilibrium steady-state can be a problem.)

A surmountable drug changes the binding affinity:

competitive ligand: $K_{d}'=K_{d}{\frac {1+[B]}{K_{b}}}$
cooperative allosteric ligand: $K_{d}'=K_{d}{\frac {K_{B}+[B]}{K_{B}+{\frac {[B]}{\alpha }}}}$

A nonsurmountable drug changes the maximum binding:

noncompetitive binding: $[R]\,t'={\frac {[R]\,t}{1+{\frac {[B]}{K_{b}}}}}$
irreversible binding

The Schild regression also can reveal if there are more than one type of receptor and it can show if the experiment was done wrong as the system has not reached equilibrium.

Radioligand binding assays

The first radio-receptor assay (RRA) was done in 1970 by Lefkowitz et al., using a radiolabeled hormone to determine the binding affinity for its receptor.^[1]

A radio-receptor assay requires the separation of the bound from the free ligand. This is done by filtration, centrifugation or dialysis.^[2]

A method that does not require separation is the scintillation proximity assay that relies on the fact that β-rays from ³H travel extremely short distances. The receptors are bound to beads coated with a polyhydroxy scintillator. Only the bound ligands to be detected.

Today, the fluorescence method is preferred to radioactive materials due to a much lower cost, lower hazard, and the possibility of multiplexing the reactions in a high-throughput manner. One problem is that fluorescent-labeled ligands have to bear a bulky fluorophore that may cause it to hinder the ligand binding. Therefore, the fluorophore used, the length of the linker, and its position must be carefully selected.

An example is by using FRET, where the ligand's fluorophore transfers its energy to the fluorophore of an antibody raised against the receptor.

Other detection methods such as surface plasmon resonance do not even require fluorophores.

References

Ligand receptor binding: Kenakin T, 1993. Pharmacological analysis of drug-receptor interaction New York: Raven Press

^ Lefkowitz RJ; Roth J; Pastan I (November 1970). "Radioreceptor assay of adrenocorticotropic hormone: new approach to assay of polypeptide hormones in plasma". Science. 170 (3958): 633–5. doi:10.1126/science.170.3958.633. PMID 4319388.
^ de Jong LA; Uges DR; Franke JP; Bischoff R (December 2005). "Receptor-ligand binding assays: technologies and applications". J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 829 (1–2): 1–25. doi:10.1016/j.jchromb.2005.10.002. PMID 16253574.

External links

curvefit.com - Dose-response curves in the presence of antagonists, for a clear explanation.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 尿路上皮（移行上皮）膀胱癌の検出のための尿中バイオマーカー urine biomarkers for the detection of urothelial transitional cell carcinoma of the bladder
2. 非転移性初期乳癌の予後と予後予測因子 prognostic and predictive factors in early nonmetastatic breast cancer
3. 凝固検査の臨床使用 clinical use of coagulation tests
4. 後天性の凝固因子阻害物質 acquired inhibitors of coagulation
5. 副甲状腺ホルモン測定およびその臨床応用 parathyroid hormone assays and their clinical use

English Journal

Synthesis and evaluation of a fluorescent non-peptidic cholecystokinin-b/gastrin receptor specific antagonist for cancer cell imaging.

Kumari S, Chowdhury J, Mishra AK, Chandna S, Saluja D, Chopra M.SourceDr. B. R. Ambedkar Center for Biomedical Research, University of Delhi, Delhi 110007 (India).
Chembiochem : a European journal of chemical biology.Chembiochem.2012 Jan 23;13(2):282-92. doi: 10.1002/cbic.201100593. Epub 2011 Dec 9.
Fluorescent labeling has enabled a better understanding of the relationships between receptor location, function, and life cycle. Each of these perspectives contributes new insights into drug action, particularly for G protein-coupled receptors (GPCRs). The aim of this study was to develop a fluores
PMID 22162268

Quantitative Preclinical Imaging of TSPO Expression in Glioma Using N,N-Diethyl-2-(2-(4-(2-18F-Fluoroethoxy)Phenyl)-5,7-Dimethylpyrazolo[1,5-a]Pyrimidin-3-yl)Acetamide.

Tang D, Hight MR, McKinley ET, Fu A, Buck JR, Smith RA, Tantawy MN, Peterson TE, Colvin DC, Ansari MS, Nickels M, Manning HC.SourceVanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, Tennessee.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.J Nucl Med.2012 Jan 17. [Epub ahead of print]
There is a critical need to develop and rigorously validate molecular imaging biomarkers to aid diagnosis and characterization of primary brain tumors. Elevated expression of translocator protein (TSPO) has been shown to predict disease progression and aggressive, invasive behavior in a variety of s
PMID 22251555

Japanese Journal

エノキタケ抽出分画のβアドレナリン受容体結合活性の評価

吉田徳,萩原えり,伊藤由彦,渡邉泰雄,山田静雄
応用薬理 76(5), 85-90, 2009-07-10
NAID 10028211916

Inhibitory Effect of Relaxin-3 on Insulin Secretion in Isolated Pancreas and Insulinoma

Yamamoto Hiroyuki,Arai Takeo,Tasaka Ryota [他],Mori Yasunori,Iguchi Kazuaki,Unno Keiko,Hoshino Minoru
Journal of health science 55(1), 132-137, 2009-02-01
… Reverse transcriptase (RT)-PCR and radioreceptor assay have shown that the relaxin-3 receptor (GPCR135) is expressed in pancreatic islets and rat insulinoma, but LGR7 is not expressed. …
NAID 110007055904